Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer By Ogkologos - August 12, 2025 748 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IoN study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and... September 21, 2021 Health of Gut Microbes May Affect Survival after Stem Cell Transplant March 25, 2020 Conducting Phase I Clinical Trials During the COVID-19 Pandemic August 5, 2020 Liquid Biopsies for Cancer: What to Know and What to Expect November 3, 2022 Load more HOT NEWS Celebrating 10 years of partnership with NIVEA Sun No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer... Outcomes From Second-Line Chemotherapy in Patients with Cholangiocarcinoma and FGFR2 Fusions New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma
